Olema Pharmaceuticals Shares Rise on Narrower Loss Per Share in 2Q

Dow Jones

Mar 17

By Katherine Hamilton

Shares of Olema Pharmaceuticals were higher after the company's loss per share was narrower than expected.

The stock rose 9.6% to $16.12 Monday. Shares have nearly quadrupled over the past 12 months.

The biopharmaceutical company, which focuses on developing breast cancer treatments, posted a second-quarter loss of 50 cents a share, compared with a 51-cent loss the year before.

The loss was also one cent narrower than analysts were expecting, according to FactSet.

Chief Executive Sean Bohen said Olema accrued gross proceeds of $218.5 million from a public offering in November.

The proceeds enable Olema to fund operations through numerous expected value-creating events with palazestrant, an endocrine therapy.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 16, 2026 12:36 ET (16:36 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2620670404"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620670404\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620670404?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620670404","market":"sh","top_or_hot":-1,"title":"Olema Pharmaceuticals Shares Rise on Narrower Loss Per Share in 2Q","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Olema Pharmaceuticals were higher after the company's loss per share was narrower than expected. \n</p>\n<p>\n  The stock rose 9.6% to $16.12 Monday. Shares have nearly quadrupled over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company, which focuses on developing breast cancer treatments, posted a second-quarter loss of 50 cents a share, compared with a 51-cent loss the year before. \n</p>\n<p>\n  The loss was also one cent narrower than analysts were expecting, according to FactSet. \n</p>\n<p>\n  Chief Executive Sean Bohen said Olema accrued gross proceeds of $218.5 million from a public offering in November. \n</p>\n<p>\n  The proceeds enable Olema to fund operations through numerous expected value-creating events with palazestrant, an endocrine therapy. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 12:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Olema Pharmaceuticals Shares Rise on Narrower Loss Per Share in 2Q</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOlema Pharmaceuticals Shares Rise on Narrower Loss Per Share in 2Q\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-17 00:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Olema Pharmaceuticals were higher after the company's loss per share was narrower than expected. \n</p>\n<p>\n  The stock rose 9.6% to $16.12 Monday. Shares have nearly quadrupled over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company, which focuses on developing breast cancer treatments, posted a second-quarter loss of 50 cents a share, compared with a 51-cent loss the year before. \n</p>\n<p>\n  The loss was also one cent narrower than analysts were expecting, according to FactSet. \n</p>\n<p>\n  Chief Executive Sean Bohen said Olema accrued gross proceeds of $218.5 million from a public offering in November. \n</p>\n<p>\n  The proceeds enable Olema to fund operations through numerous expected value-creating events with palazestrant, an endocrine therapy. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 12:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620670404","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620670404","pubTimestamp":1773678960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Olema Pharmaceuticals were higher after the company's loss per share was narrower than expected.The stock rose 9.6% to $16.12 Monday. Shares have nearly quadrupled over the past 12 months.The biopharmaceutical company, which focuses on developing breast cancer treatments, posted a second-quarter loss of 50 cents a share, compared with a 51-cent loss the year before.The loss was also one cent narrower than analysts were expecting, according to FactSet.Chief Executive Sean Bohen said Olema accrued gross proceeds of $218.5 million from a public offering in November.The proceeds enable Olema to fund operations through numerous expected value-creating events with palazestrant, an endocrine therapy.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","OLMA":"Olema Pharmaceuticals, Inc."},"translate_title":"Olema Pharmaceuticals股价因第二季度每股亏损收窄而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OLMA":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of Olema Pharmaceuticals were higher after the company's loss per share was narrower than expected. \n\n\n  The stock rose 9.6% to $16.12 Monday. Shares have nearly quadrupled over the past 12 months. \n\n\n  The biopharmaceutical company, which focuses on developing breast cancer treatments, posted a second-quarter loss of 50 cents a share, compared with a 51-cent loss the year before. \n\n\n  The loss was also one cent narrower than analysts were expecting, according to FactSet. \n\n\n  Chief Executive Sean Bohen said Olema accrued gross proceeds of $218.5 million from a public offering in November. \n\n\n  The proceeds enable Olema to fund operations through numerous expected value-creating events with palazestrant, an endocrine therapy. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 12:36 ET (16:36 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}